Cerebrospinal fluid sampling by lumbar puncture in rats – repeated measurements of nitric oxide metabolites

2005 ◽  
Vol 145 (1-2) ◽  
pp. 89-95 ◽  
Author(s):  
Xianjun Wang ◽  
Shinji Kimura ◽  
Takashi Yazawa ◽  
Naoto Endo
Author(s):  
Bruno L. Santos-Lobato ◽  
Mariza Bortolanza ◽  
Lucas César Pinheiro ◽  
Marcelo E. Batalhão ◽  
Ângela V. Pimentel ◽  
...  

1998 ◽  
Vol 4 (1) ◽  
pp. 27-30 ◽  
Author(s):  
G Giovannoni

Nitric oxide is hypothesised to play a role in the immunopathogenesis of multiple sclerosis. Raised cerebrospinal fluid and serum levels of the nitric oxide metabolites nitrate and nitrite have been described in patients with multiple sclerosis. Cerebrospinal fluid and serum nitrate and nitrite were measured in patients with multiple sclerosis, inflammatory and non-inflammatory neurological diseases, and correlated with the albumin quotient, an index of blood-brain-barrier dysfunction. Patients undergoing diagnostic lumbar and vene puncture were prospectively recruited, clinical data were obtained from the hospital records, and the CSF and serum nitrate and nitrite levels were measured by the nitrate reductase and Griess reaction methods. Nitrate and nitrite, were raised in the CSF and serum of patients with multiple sclerosis and other inflammatory neurological diseases compared to patients with non-inflammatory neurological disorders (median nitrate and nitrite: cerebrospinal fluid=10.3 μM vs 15.4 μMvs 6.6 μM, P50.001, and serum=49.0 μM vs 46.4 μM vs 38.8 μM, P=0.02, respectively). CSF nitrate and nitrite levels correlated with the albumin quotient (n=59, r=0.42, P50.001). This study provides further evidence for a role of nitric oxide in the immunopathogenesis of multiple sclerosis and supports a role for nitric oxide as a possible mediator of inflammatory blood-brain-barrier dysfunction.


Neuroreport ◽  
1999 ◽  
Vol 10 (2) ◽  
pp. 275-279 ◽  
Author(s):  
Shinji Kimura ◽  
Kenji Watanabe ◽  
Yoichi Yajiri ◽  
Takashi Motegi ◽  
Yuki Masuya ◽  
...  

2001 ◽  
Vol 29 (1) ◽  
pp. 77-79 ◽  
Author(s):  
Daikai Sadamitsu ◽  
Yasuhiro Kuroda ◽  
Tsutomu Nagamitsu ◽  
Ryosuke Tsuruta ◽  
Takeshi Inoue ◽  
...  

2002 ◽  
Vol 9 (4) ◽  
pp. 413-418 ◽  
Author(s):  
Dj. Miljkovic ◽  
J. Drulovic ◽  
V. Trajkovic ◽  
S. Mesaros ◽  
I. Dujmovic ◽  
...  

2020 ◽  
Author(s):  
Bruno L. Santos-Lobato ◽  
Mariza Bortolanza ◽  
Marcelo E. Batalhão ◽  
Ângela V. Pimentel ◽  
Evelin Capellari-Carnio ◽  
...  

AbstractIntroductionLevodopa-induced dyskinesias (LID) in Parkinson’s disease (PD) are frequent complications, and nitric oxide has a role on its pathophysiology. The present work aims to investigate CSF levels of nitric oxide metabolites nitrite and nitrate (NOx) in patients with PD and LID.MethodsWe measured CSF NOx levels in patients with PD with and without LID, and in healthy controls. The levels of CSF NOx levels were measured by ozone-based chemiluminescence.Results67 participants were enrolled. CSF NOx levels were higher in patients with PD with LID than in healthy controls (Kruskal-Wallis statistics = 7.24, p = 0.02). CSF NOx levels did not correlate with other clinical variables.ConclusionWe reported higher levels of nitric oxide in the CSF of patients with PD and LID.Highlights–Nitric oxide has a role on levodopa-induced dyskinesias in Parkinson’s disease–We measured CSF nitrite and nitrate in Parkinson’s disease patients with dyskinesias–CSF nitrite and nitrate were higher in Parkinson’s disease patients with dyskinesias


PLoS ONE ◽  
2018 ◽  
Vol 13 (5) ◽  
pp. e0196696
Author(s):  
Sharon Y. Y. Low ◽  
Chen Min Wei ◽  
Kenneth T. E. Chang ◽  
Chan Yiong Huak ◽  
Ng Lee Ping ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document